![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif) |
|
Multiple Cancer Types - Featured Clinical Trials
1. Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention (Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif)
2. Targeted Treatment for Advanced Solid Tumors (Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors.
![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif)
3. Batracylin for Patients with Advanced Solid Tumors or Lymphoma (Posted: 04/01/2008) - In this phase I trial, patients with solid tumors or lymphomas for which standard therapies do not exist or are of minimum benefit and who are slow acetylators, as determined by a blood test, will be treated with increasing doses of the drug batracylin.
![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif)
4. Inhibiting Tumor Angiogenesis in Children (Posted: 01/22/2008) - In this trial, researchers are testing an angiogenesis inhibitor called cediranib in pediatric patients who have solid tumors (except brain tumors) or acute myeloid leukemia (AML), a type of blood cancer.
![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif)
5. Radiation Therapies to Treat Brain Metastases (Posted: 08/21/2007) - In this clinical trial, doctors are comparing stereotactic radiosurgery alone against stereotactic radiosurgery followed by whole-brain radiotherapy in patients with 1-3 cerebral metastases resulting from cancer elsewhere in the body.
1 2 3 4 Next > |
|
![](https://webarchive.library.unt.edu/eot2008/20090116014349im_/http://www.cancer.gov/images/spacer.gif) |